Figure S5 from Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

Jones, Robert B.; Farhi, Jonathan; Adams, Miranda; Parwani, Kiran K.; Cooper, Garrett W.; Zecevic, Milica; Lee, Richard S.; Hong, Andrew L.; Spangle, Jennifer M.

doi:10.1158/2767-9764.22546218.v1

Figure S5 from Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

https://doi.org/10.1158/2767-9764.22546218

journal contribution

posted on 2023-04-04, 02:03 authored by Robert B. Jones, Jonathan Farhi, Miranda Adams, Kiran K. Parwani, Garrett W. Cooper, Milica Zecevic, Richard S. Lee, Andrew L. Hong, Jennifer M. Spangle

<p>Figure S5 shows that combined PI3K and MLL inhibition provides therapeutic benefit in vitro and in vivo</p>

Funding

HHS | NIH | National Cancer Institute (NCI)

HHS | NIH | National Institute of General Medical Sciences (NIGMS)

U.S. Department of Defense (DOD)

American Cancer Society (ACS)

EU | School of Medicine, Emory University (Emory University School of Medicine)

History

Related Materials

1.
DOI - Is supplement to Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

ARTICLE ABSTRACT

Here the authors leverage PI3K/AKT-driven chromatin modification to identify histone methyltransferases as a therapeutic target. Dual PI3K and MLL inhibition synergize to reduce clonogenicity and cell proliferation, and promote in vivo tumor regression. These findings suggest patients with PIK3CA-mutant, HR+ breast cancer may derive clinical benefit from combined PI3K/MLL inhibition.